Quarterly Appendix 4C and Activities Report

• BZDS1901, a groundbreaking CAR-T product for mesothelioma and other solid cancers to be co-developed with Shanghai Cell Therapy Group Co Ltd (“SHcell”), formally launching AdCella’s “East to West” cellular immunotherapy operations • $2.8 million raised via private placements (includes $1.2 million raised post period end) • $0.93 million R&D Tax Incentive (“RDTI”) refund (includes $0.15 million p